
The drawbacks of the platinum chemotherapy agents cisplatin, carboplatin and oxaliplatin have inspired the development of compounds with different mechanisms of action. Polyaromatic platinum complexes (PPCs) are a promising anticancer alternative; these bind reversibly with DNA through the insertion of a planar aromatic moiety between nucleobases in a process known as intercalation. PPCs have demonstrated in vitro behaviour remarkably different from that of cisplatin and exhibited cytotoxicity up to one hundred times higher than that of cisplatin in many cell lines. This microreview primarily discusses 1,10‐phenanthroline‐based complexes of the type [Pt(PL)(AL)]2+ (where PL is a polyaromatic ligand and AL is an ancillary ligand), including their cytotoxicity, DNA‐binding behaviour and biological activity in vitro and in vivo. Other PPCs within the field, including dual‐mode DNA binders incorporating tethered acridines and other potently cytotoxic complexes, are also covered.
intercalating agents, platinum compounds, therapeutic use, cancer, DNA-ligand interactions, 030401 - Biologically Active Molecules
intercalating agents, platinum compounds, therapeutic use, cancer, DNA-ligand interactions, 030401 - Biologically Active Molecules
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 50 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
